Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the phase 3, pooled TEMSO (NCT00134563) and TOWER (NCT00751881) dataset is to evaluate the effect of teriflunomide treatment on annualised relapse rate and disability worsening across patient subgroups defined according to prior disease-modifying therapy exposure. This analysis provides further supportive evidence for a consistent effect of teriflunomide across a broad range of patients with relapsing MS, including patients who have used and discontinued other disease-modifying therapies.
Freedman, MS., Wolinsky, JS., Comi, G., Kappos, L., Olsson, TP., Miller, AE., Thangavelu, K., Benamor, M., Truffinet, P., O'Connor, PW., Study Group, TEMSO., & Group, TOWER. S. (2018). The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. Multiple Sclerosis, 24(4), 535-539. https://doi.org/10.1177/1352458517695468